Overview

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Status:
Terminated
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This is a phase II study that combines Trastuzumab with Pertuzumab to see how it works in women age greater than 60 who have been diagnosed with HER2/neu overexpressed locally advanced and/or metastatic breast carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Katherine Tkaczuk
Collaborator:
Genentech, Inc.
Treatments:
Anastrozole
Estradiol
Fulvestrant
Pertuzumab
Trastuzumab